Findings from the Treatment of
Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes o
Preserved Cardiac
Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a
preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes o
preserved ejection fraction in a study funded by the National Heart,
Lung and Blood Institute, National Institutes of Health.
«Future efforts to
preserve or restore aging - and disease - related loss of
lung function will need to take such tissue mechanical and cellular phenotypic changes into account,» the researchers wrote.